Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

Video

Virtual Conference Live

Inizio

Report

Digital Health Tools - Physician Trends

Inizio

Webcast

Oncology landscape: How innovative market research methods can navigate you to success

Inizio

- PMLiVE

Oxford PharmaGenesis named in Medical Marketing and Media’s Agency 100 report

Media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in the latest Agency 100 – the annual definitive ‘who’s who’ ranking of the sector’s top healthcare marketing firms...

- PMLiVE

How can compelling healthcare communications support HCPs with their pandemic patient backlog?

Read our latest article, written by Chris Barton (Strategic Solutions Director), who shares his thoughts on how pharmaceutical companies and medical communication companies, like Bedrock, can support healthcare systems to...

Bedrock Healthcare Communications

- PMLiVE

Pharma marketers’ blog: How to get your tactical mix right in the new normal

Optimising your promotional effectiveness and ultimate customer experiences

MSL Digital Offices and HCP Community Boards: A Customer Story

Learn how our client is leveraging the Impetus InSite Platform® to host company-wide “digital offices” and community boards for MSLs and HCPs to connect one-on-one or one-to-many.

Impetus Digital

- PMLiVE

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

The Innovative Licensing and Access Pathway scheme aims to help speed approval of innovative treatments

- PMLiVE

Moderna says its COVID-19 vaccine appears effective against Delta and other variants

Earlier this year, the company revealed early evidence that its booster jabs may be effective against ‘variants of concern’

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links